Cardiff Oncology Inc reports results for the quarter ended December 31 - Earnings Summary

• Cardiff Oncology Inc CRDF.OQ reported a quarterly adjusted loss of 22 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -21 cents. The mean expectation of six analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -29 cents to -20 cents per share.

• Revenue fell 3.2% to $151.00 thousand from a year ago; analysts expected $94.17 thousand.

• Cardiff Oncology Inc's reported EPS for the quarter was a loss of 22 cents​.

• The company reported a quarterly loss of $11.79 million.

• Cardiff Oncology Inc shares had risen by 2.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 1.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Cardiff Oncology Inc is $11.50

This summary was machine generated from LSEG data February 28 at 12:58 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)